These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2769992)

  • 1. [Clinical application and significance of drug delivery systems. An immunosuppressant, cyclosporin A].
    Takada K
    Nihon Rinsho; 1989 Jun; 47(6):1308-15. PubMed ID: 2769992
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxicologic evaluation of the new cyclosporin derivative, SDZ IMM 125, in a comparative, subchronic toxicity study in rats.
    Donatsch P; Mason J; Richardson BP; Ryffel B
    Transplant Proc; 1992 Aug; 24(4 Suppl 2):39-42. PubMed ID: 1496685
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity, and pharmacokinetics in Lewis rats.
    Hagberg RC; Hoyt EG; Billingham ME; Sibley RK; Starnes VA; Baldwin JC
    J Heart Transplant; 1988; 7(5):359-69. PubMed ID: 3058906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Differentiation of the degree of bioavailability of peroral drug forms of tetracycline hydrochloride in experiments on laboratory animals].
    Zak AF; Ermolova OB
    Antibiotiki; 1976 Feb; 21(2):151-5. PubMed ID: 1275466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of digoxin in man after oral administration of preparations with different dissolution rate.
    Nyberg L
    Acta Pharmacol Toxicol (Copenh); 1977; 40 Suppl 3():1-48. PubMed ID: 301340
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres.
    Yanagawa A; Iwayama T; Saotome T; Shoji Y; Takano K; Oka H; Nakagawa T; Mizushima Y
    J Microencapsul; 1989; 6(2):161-4. PubMed ID: 2723958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical application and significance of drug delivery systems. Cytokine].
    Yoshikawa H
    Nihon Rinsho; 1989 Jun; 47(6):1324-8. PubMed ID: 2671443
    [No Abstract]   [Full Text] [Related]  

  • 8. Enteric solid dispersion of cyclosporin A (CyA) having potential to improve availability of CyA in rabbit.
    Takada K; Oh-hashi M; Furuya Y; Yoshikawa H; Muranishi S
    Chem Pharm Bull (Tokyo); 1989 Sep; 37(9):2542-4. PubMed ID: 2605708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cyclosporin in man following a single oral dose: relationship to body fat content.
    Waters MR; Albano JD; Sharman VL; Raman GV
    Nephrol Dial Transplant; 1989; 4(1):71-4. PubMed ID: 2494602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics.
    Takada K; Oh-hashi M; Furuya Y; Yoshikawa H; Muranishi S
    Chem Pharm Bull (Tokyo); 1989 Feb; 37(2):471-4. PubMed ID: 2743495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A as a tool for experimental and clinical transplantation.
    Tutschka PJ
    Biomed Pharmacother; 1982; 36(8-9):341-4. PubMed ID: 6763540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
    Li PK; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug formulation and biologic availability.
    Poole JW
    Semin Drug Treat; 1971 Sep; 1(2):148-76. PubMed ID: 5153883
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous absorption of cyclosporine in rabbits.
    Shah AK; Sawchuk RJ; Gratwohl A; Baldomero H; Speck B
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):710-4. PubMed ID: 3363667
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current aspects in organ transplantation].
    Ryffel B
    Schweiz Rundsch Med Prax; 1989 Sep; 78(37):997-1002. PubMed ID: 2678372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads.
    Hosny EA; el-Mahrouk GM; Gouda MW
    Drug Dev Ind Pharm; 1998 Jul; 24(7):661-6. PubMed ID: 9876511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of drug interactions of cyclosporin].
    Billaud EM; Kreft-Jais C; De la Tour du Pin F; Alexandre JM
    Presse Med; 1988 Dec; 17(43):2293-5. PubMed ID: 2905455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic activity of cyclosporine metabolites.
    Sewing KF; Christians U; Kohlhaw K; Radeke H; Strohmeyer S; Kownatzki R; Budniak J; Schottmann R; Bleck JS; Almeida VM
    Transplant Proc; 1990 Jun; 22(3):1129-34. PubMed ID: 2349673
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.
    Storpirtis S; Rodrigues D
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1101-7. PubMed ID: 9876567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of formulation of enteric coated tablets on the bioavailability of the drug. 5th Part: Bioavailability of Riboflavin enteric coated tablets (author's transl)].
    Delporte JP; Jaminet F
    J Pharm Belg; 1976; 31(4):341-54. PubMed ID: 978382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.